Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population
Abstract Challenges in drug development for rare diseases such as pulmonary arterial hypertension can be addressed through the use of mathematical modeling. In this study, a quantitative systems pharmacology model of pulmonary arterial hypertension pathophysiology and pharmacology was used to predic...
Saved in:
Main Authors: | Andrew E. Stine, Jignesh Parmar, Amy K. Smith, Zachary Cummins, Narasimha Rao Pillalamarri, R. Joseph Bender |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | npj Systems Biology and Applications |
Online Access: | https://doi.org/10.1038/s41540-024-00481-y |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil
by: Piotr Kędzierski, et al.
Published: (2025-01-01) -
Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
by: Ci Song, et al.
Published: (2022-06-01) -
Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil
by: Daniel Lachant, DO, et al.
Published: (2025-05-01) -
Diagnosis and Management of Pulmonary Arterial Hypertension
by: Jeanne Houtchens, et al.
Published: (2011-01-01) -
Echocardiographic evaluation of the size of the main pulmonary artery and right pulmonary artery in dogs with pulmonary hypertension
by: Giovanni Grosso, et al.
Published: (2025-01-01)